Neuroscientist

Ibogaine By David Dardashti Announces Female Neuroscientist To Offer Suggestions on Treating Women with Substance Abuse

Retrieved on: 
Monday, April 22, 2024
Comprehension, Substance abuse, Environment, Ibogaine, Human, Patient, Addiction, Knowledge, Woman, Neuroscientist, Female, Drug

MIAMI, April 22, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti , a prominent drug addiction treatment center, is advancing their dedication to aiding women struggling with substance abuse, under the guidance of their Neuroscientist, Misty Huckabey.

Key Points: 
  • MIAMI, April 22, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti , a prominent drug addiction treatment center, is advancing their dedication to aiding women struggling with substance abuse, under the guidance of their Neuroscientist, Misty Huckabey.
  • Ms. Huckabey's method of treating female addiction patients is shaped by her profound comprehension of the biological variances between males and females.
  • This insight enables her to customize treatment strategies to cater to the distinct requirements and obstacles women encounter during recovery.
  • “I am honored to collaborate with Ibogaine By David Dardashti and be the voice of reason for gender related care in the treatment of women,” said Misty Huckabey.

The M Factor Film exploring menopause debuts October 18

Retrieved on: 
Tuesday, April 2, 2024
Emmy Awards, Health, Cardiovascular disease, Physician, PBS, Menopause, NCMP, Quality of life, Osteoporosis, Neuroscientist, Silence, Workplace, Dementia

LOS ANGELES, April 2, 2024 /PRNewswire/ -- "The M Factor: Shredding the Silence on Menopause" is a groundbreaking documentary that will empower and educate the 1.1 billion women worldwide who will be in menopause in 2025.

Key Points: 
  • LOS ANGELES, April 2, 2024 /PRNewswire/ -- "The M Factor: Shredding the Silence on Menopause" is a groundbreaking documentary that will empower and educate the 1.1 billion women worldwide who will be in menopause in 2025.
  • Despite its universality, menopause has remained shrouded in stigma, silence and misunderstanding, contributing to the broader women's health crisis.
  • "The M Factor" features renowned doctors like Dr. Sharon Malone, M.D.
  • The producers are launching a 12-city screening tour, ensuring that "The M Factor" sparks conversations and drives change in women's midlife wellness.

Nicole M. Avena, Ph.D., Offers Expert Tips to Stay Healthy Ahead of the Holidays

Retrieved on: 
Tuesday, November 21, 2023
Health, Infectious Diseases, Fitness & Nutrition, COVID-19, General Health, Vitamins, Supplements, Honey, Immune system, Food, Neuroscientist, Tablet, Weather, Friends, Virus, Water, CDC, Family, Mitigation, Environment, Travel, Vaccine, Dietary supplement

"As we approach the cold and flu season, it's crucial to adopt measures to support our immune system and overall health.

Key Points: 
  • "As we approach the cold and flu season, it's crucial to adopt measures to support our immune system and overall health.
  • These tips are designed to provide guidance for individuals looking to navigate the season and keep immunity high,” states Dr. Avena.
  • Prevent the Spread: Clean and disinfect your home before hosting guests to minimize the spread of germs.
  • Taking this step before more people enter your common environment can create a healthier space for all.

BrainCheck Celebrates U.S. FDA Approval of Leqembi® and Empowers Customers to Lead the Way in Early Detection of Cognitive Impairment

Retrieved on: 
Monday, July 17, 2023
Disease, Education, Alzheimer's disease, Montreal Cognitive Assessment, Stanford University, Anxiety, Lecanemab, Deficit spending, Dignity, MBA, Research, Doctor of Philosophy, Science, Dementia, AAIC, Patient, Physician, Neurology, Baylor College of Medicine, Diagnosis, Knowledge, FDA, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Conference, Neuroscientist, Food, Pharmaceutical industry, Nursing, Medical imaging, Hospital

AUSTIN, Texas, July 17, 2023 /PRNewswire/ -- BrainCheck, Inc. celebrates the U.S. Food and Drug Administration (FDA)'s recent decision to approve Leqembi® (lecanemab, Eisai/Biogen), for the treatment of early Alzheimer's disease. BrainCheck's comprehensive cognitive assessment and care management platform is empowering customers to lead the way in the early detection of cognitive impairment. Kim Rodriguez, CEO, and Matt Cerullo, Chief Revenue Officer, will attend the Alzheimer's Association International Conference (AAIC) in Amsterdam, Netherlands from July 16-20 to share BrainCheck's technology with the global dementia research community.

Key Points: 
  • BrainCheck's comprehensive cognitive assessment and care management platform is empowering customers to lead the way in the early detection of cognitive impairment.
  • "The U.S. FDA's approval of Leqembi® marks a major milestone in the fight against Alzheimer's disease.
  • With the approval specifically focused on the treatment of patients with early forms of disease, such as mild cognitive impairment or mild dementia, early detection has never been more important," said Kim Rodriguez, CEO of BrainCheck.
  • "We developed the BrainCheck platform because we believe that in the battle against Alzheimer's disease and dementia, early detection is the best defense.

With Growing Global Safety Concerns Over Sleep Aids, FitBiomics Co-Authors Study Showcasing New Probiotic Alternative

Retrieved on: 
Tuesday, June 27, 2023
Sulfotransferase, Science, Human, Veillonella, Lactobacillus, Nature Medicine, Sleep, Scientific American, Physiology, Research, Inflammation, History, Doctor of Philosophy, Harvard Medical School, Defecation, Oxidative stress, The New York Times, Sleep disorder, Sleep deprivation, NPR, Health, Probiotic, Neuroscientist, Safety, Exertion, Pharmaceutical industry, Dietary supplement, Nursing, Microbiology

NEW YORK, June 27, 2023 /PRNewswire/ -- Researchers are unveiling the remarkable effects of Nella, a multi-strain probiotic consortium developed by microbiome innovation company FitBiomics, on promoting sleep quality in humans in a study released today on World Microbiome Day. With a cutting-edge, two-phase clinical approach, the study showcases Nella's broader health benefits along with its potential to transform the way we approach sleep and probiotic alternatives to sleep aids.

Key Points: 
  • With a cutting-edge, two-phase clinical approach, the study showcases Nella's broader health benefits along with its potential to transform the way we approach sleep and probiotic alternatives to sleep aids.
  • "Our study indicates that the probiotic consortium in Nella significantly enhances sleep quality which is noteworthy given the growing concerns around the use of traditional sleep aids."
  • Nella's probiotic consortium offers a safe and potentially more consistent solution to sleep-related issues compared to current sleep aids.
  • "This study marks an important milestone in our understanding of the role probiotics play in improving sleep quality and overall health.

Psychedelic Science 2023 Announces Final Agenda, Additional Featured Speakers, and Special Local Day Pass Option

Retrieved on: 
Tuesday, June 13, 2023
Momentum, Katherine, Toms Shoes, Stanford School, Catherine Oxenberg, Exhibition, Education, Culture, Shoe, Policy, Psychedelic drug, IOS, Multidisciplinary Association for Psychedelic Studies, Stanford University School of Medicine, MAPS, Google Play, Conference, Neuroscientist, Shoemaking, Nightclub, Neuroscience

DENVER, June 13, 2023 (GLOBE NEWSWIRE) -- Psychedelic Science 2023, the breakthrough psychedelic conference hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) and organized by Momentum Events, announced it has released the final agenda including additional featured speakers and a new Friday Local Day Pass option for the world’s most compelling conference within the psychedelic ecosystem, taking place June 19-23, 2023 in Denver, Colorado.

Key Points: 
  • With an estimated 10,000 attendees, the Psychedelic Science 2023 agenda will feature five days of panels, workshops, and lectures from leaders and visionaries in psychedelic research, education, policy, business, culture, and communities.
  • Conference tracks will be complemented by pre-conference workshops; an exhibit hall; and an interactive installation space featuring artists, musicians, and other vendors from around the world.
  • Interested individuals will be eligible to purchase a one-day conference registration to attend the conference on Friday, June 23rd.
  • Local day passes will be available beginning Tuesday, June 13th and can be purchased at PsychedelicScience.org .

BioFuture™ Conference Brings Together Stakeholders In Transformative Healthcare Summit

Retrieved on: 
Thursday, November 17, 2022
Biotechnology, Practice Management, Telemedicine, Virtual Medicine, Pharmaceutical, Health, Artificial Intelligence, Health Technology, Technology, AI, City, Lotte New York Palace Hotel, Health, Demy, Therapy, Big data, Alzheimer's disease, Stanford University, Eli Lilly, Virtual reality, Neuroscientist, Virtual, Johnson & Johnson, Learning, VR, Biotechnology, Pharmaceutical industry, Management

Held at the Lotte New York Palace from November 7-9 and the following week virtually, the event brought together healthcare and biotechnology leaders, investors, sector stakeholders, and bleeding-edge disruptors who are reimagining therapeutics.

Key Points: 
  • Held at the Lotte New York Palace from November 7-9 and the following week virtually, the event brought together healthcare and biotechnology leaders, investors, sector stakeholders, and bleeding-edge disruptors who are reimagining therapeutics.
  • The 2022 program featured insights from top biotech, digital medicine, virtual reality, and healthcare executives across a broad spectrum of areas of expertise.
  • BioFuture featured more than 100 speakers who examined the exciting convergence between rapidly evolving fields, including biopharma, digital medicine, big data, AI, VR, healthcare systems, and more.
  • Its unique events facilitate networking on a global scale, including Biotech Showcase, BioFuture, Biotech CEO Summit Europe, Biotech CEO Summit, and Demy-Colton Virtual Salons.

Eight Sleep Hires Former Peloton Global Chief Sales Officer, Tim Shannehan, As New Chief Revenue Officer

Retrieved on: 
Thursday, November 3, 2022
Technology, Fitness & Nutrition, Health Technology, Software, Other Health, Hardware, Health, General Health, Artificial Intelligence, Neuroscientist, E-commerce, Invention, Awareness, Clothing, Growth, Multimedia, D2C, Athlete, Sleep, Industry, AI, Toyota Racing (Formula One team), Executive, Mercedes-AMG, Workplace, Movement, CEO, CrossFit, Eight Sleep, Research, TIME, Mercedes, Travel, Entrepreneurship, Health, Globalization, CrossFit Games, POD, Marketing, Fast Company, Software, Inspirato, United Kingdom, Pharmaceutical industry, Hotel, Sales, Sport

Eight Sleep, the worlds first sleep fitness company has appointed former Chief Sales Officer at Peloton, Tim Shannehan, as Chief Revenue Officer.

Key Points: 
  • Eight Sleep, the worlds first sleep fitness company has appointed former Chief Sales Officer at Peloton, Tim Shannehan, as Chief Revenue Officer.
  • View the full release here: https://www.businesswire.com/news/home/20221103005277/en/
    The Pod 3 from Eight Sleep (Photo: Business Wire)
    Shannehan joins Eight Sleep after nearly 8 years at Peloton.
  • He joined Peloton in the role of Chief Revenue Officer where he led the teams responsible for scaling and growing revenue to over $4B.
  • During this time, Tim oversaw all global sales channels including Ecommerce, Retail, Inside Sales, and the development and launch of Hospitality, Corporate Wellness, and Sales Partnerships.

Parker Seminars to Host NeuroCon 2022 Event on Parker University Campus July 29-30

Retrieved on: 
Monday, July 18, 2022
Research, Patient, Lists of diseases, University College London, Neuroscientist, GLOBE, Education, Student, St. Basil-the-Great College School, Nervous system, Stanford University School of Medicine, MIT, Teachers College, Columbia University, Cognitive neuroscience, Parker University, Management, Neuroscience

Dallas, Texas, July 18, 2022 (GLOBE NEWSWIRE) -- From July 29-30, 2022, join Parker Seminars for an exciting in-person, two-day event designed specifically for healthcare professionals!

Key Points: 
  • Dallas, Texas, July 18, 2022 (GLOBE NEWSWIRE) -- From July 29-30, 2022, join Parker Seminars for an exciting in-person, two-day event designed specifically for healthcare professionals!
  • Taking place on the Parker University campus in Dallas, Texas, attendees will hear from industry experts and speakers, earn CE hours, and network with each other and exhibitors.
  • NeuroCon 2022 will provide attendees with the expertise needed to equip themselves and their patients with the most relevant knowledge for maximizing the brains potential.
  • Parker University, the fourth-fastest growing college in Texas and the fastest-growing college in Dallas, was founded in 1982 by Dr. James William Parker (formerly Parker College of Chiropractic).

AviadoBio Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, May 12, 2022
Neurosurgery, LifeArc, NEA, Dementia, Capital, Ludwig Cancer Research, Ohio State University College of Medicine, Molecular medicine, Radiology, University of California, University, Neuroscientist, Twitter, SAB, FTD, Master of Science, Autosome, Gene, Neurodegeneration, Research, Brain, Board, UMMS, Frontotemporal dementia, Harvard Medical School, Department, Death, Doctor of Philosophy, Language, Amyotrophic lateral sclerosis, University college, Central nervous system, LinkedIn, Massachusetts General Hospital, Coronavirus Scientific Advisory Board (Turkey), ALS, Assistant, GRN, Patient, AAV, WWE Performance Center, DDF, New Enterprise Associates, Journal of Cellular and Molecular Medicine, Diagnosis, CEO, Pharmaceutical industry, Vaccine, Management, MD, Neurology, Neuroscience

Includes prominent international scientific and clinical pioneers across neurodegeneration research, neurosurgical drug delivery and neurological gene therapy

Key Points: 
  • Includes prominent international scientific and clinical pioneers across neurodegeneration research, neurosurgical drug delivery and neurological gene therapy
    London, UK, May 12, 2022 AviadoBio, a pioneering, pre-clinical stage, gene therapy company focused on developing and delivering transformative medicines for people with neurodegenerative disorders, announces that it has established a Scientific Advisory Board (SAB) comprising world-leading experts in neurodegenerative diseases, neurosurgical drug delivery and gene therapy development.
  • Lisa Deschamps, CEO of AviadoBio, said: "Attracting such an esteemed and diverse group of neurodegenerative disease, neurosurgery and gene therapy experts to the AviadoBio team is a testament to the strength of our differentiated approach.
  • Professor Chris Shaw, commented: I am delighted to Chair AviadoBios Scientific Advisory Board, which includes world-leading experts in their respective fields.
  • For more information, please visit www.aviadobio.com and follow us at Twitter @AviadoBio and LinkedIn AviadoBio.